QQQ   386.20 (+0.80%)
AAPL   165.32 (+2.15%)
MSFT   326.19 (+0.98%)
FB   317.87 (+3.59%)
GOOGL   2,863.10 (+0.81%)
AMZN   3,427.37 (+1.11%)
TSLA   1,009.01 (-0.59%)
NVDA   300.37 (-2.14%)
BABA   123.60 (+10.40%)
NIO   32.34 (+0.59%)
CGC   10.15 (+1.60%)
AMD   139.06 (-3.44%)
GE   96.01 (+3.49%)
MU   82.45 (+1.02%)
T   23.28 (-0.77%)
F   19.22 (+0.42%)
DIS   150.37 (+2.84%)
PFE   51.48 (-5.14%)
AMC   28.79 (-0.76%)
ACB   5.97 (+2.58%)
BA   205.88 (+3.72%)
QQQ   386.20 (+0.80%)
AAPL   165.32 (+2.15%)
MSFT   326.19 (+0.98%)
FB   317.87 (+3.59%)
GOOGL   2,863.10 (+0.81%)
AMZN   3,427.37 (+1.11%)
TSLA   1,009.01 (-0.59%)
NVDA   300.37 (-2.14%)
BABA   123.60 (+10.40%)
NIO   32.34 (+0.59%)
CGC   10.15 (+1.60%)
AMD   139.06 (-3.44%)
GE   96.01 (+3.49%)
MU   82.45 (+1.02%)
T   23.28 (-0.77%)
F   19.22 (+0.42%)
DIS   150.37 (+2.84%)
PFE   51.48 (-5.14%)
AMC   28.79 (-0.76%)
ACB   5.97 (+2.58%)
BA   205.88 (+3.72%)
QQQ   386.20 (+0.80%)
AAPL   165.32 (+2.15%)
MSFT   326.19 (+0.98%)
FB   317.87 (+3.59%)
GOOGL   2,863.10 (+0.81%)
AMZN   3,427.37 (+1.11%)
TSLA   1,009.01 (-0.59%)
NVDA   300.37 (-2.14%)
BABA   123.60 (+10.40%)
NIO   32.34 (+0.59%)
CGC   10.15 (+1.60%)
AMD   139.06 (-3.44%)
GE   96.01 (+3.49%)
MU   82.45 (+1.02%)
T   23.28 (-0.77%)
F   19.22 (+0.42%)
DIS   150.37 (+2.84%)
PFE   51.48 (-5.14%)
AMC   28.79 (-0.76%)
ACB   5.97 (+2.58%)
BA   205.88 (+3.72%)
QQQ   386.20 (+0.80%)
AAPL   165.32 (+2.15%)
MSFT   326.19 (+0.98%)
FB   317.87 (+3.59%)
GOOGL   2,863.10 (+0.81%)
AMZN   3,427.37 (+1.11%)
TSLA   1,009.01 (-0.59%)
NVDA   300.37 (-2.14%)
BABA   123.60 (+10.40%)
NIO   32.34 (+0.59%)
CGC   10.15 (+1.60%)
AMD   139.06 (-3.44%)
GE   96.01 (+3.49%)
MU   82.45 (+1.02%)
T   23.28 (-0.77%)
F   19.22 (+0.42%)
DIS   150.37 (+2.84%)
PFE   51.48 (-5.14%)
AMC   28.79 (-0.76%)
ACB   5.97 (+2.58%)
BA   205.88 (+3.72%)
NASDAQ:ADAP

Adaptimmune Therapeutics Stock Forecast, Price & News

$3.59
+0.01 (+0.28%)
(As of 12/6/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.47
$3.63
50-Day Range
$3.58
$5.68
52-Week Range
$3.37
$7.34
Volume
1.12 million shs
Average Volume
1.20 million shs
Market Capitalization
$560.77 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2
30 days | 90 days | 365 days | Advanced Chart
Receive ADAP News and Ratings via Email

Sign-up to receive the latest news and ratings for Adaptimmune Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Adaptimmune Therapeutics logo

About Adaptimmune Therapeutics

Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.

Headlines

Why Adaptimmune Therapeutics Stock Is Crashing Today
December 1, 2021 |  finance.yahoo.com
Adaptimmune Therapeutics (NASDAQ:ADAP) Stock Price Down 5.3%
December 1, 2021 |  americanbankingnews.com
Adaptimmune Bullish On Meeting Endpoint For Soft Tissue Cancer Trial
November 11, 2021 |  markets.businessinsider.com
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ADAP
Employees
2,020
Year Founded
N/A

Sales & Book Value

Annual Sales
$3.96 million
Book Value
$1.54 per share

Profitability

Net Income
$-130.09 million
Net Margins
-2,499.92%
Pretax Margin
-2,489.75%

Debt

Price-To-Earnings

Miscellaneous

Free Float
126,697,000
Market Cap
$560.77 million
Optionable
Optionable

Company Calendar

Last Earnings
11/04/2021
Today
12/06/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/24/2022

MarketRank

Overall MarketRank

1.95 out of 5 stars

Medical Sector

695th out of 1,390 stocks

Biological Products, Except Diagnostic Industry

106th out of 202 stocks

Analyst Opinion: 3.0Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -












Adaptimmune Therapeutics (NASDAQ:ADAP) Frequently Asked Questions

Is Adaptimmune Therapeutics a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adaptimmune Therapeutics in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" Adaptimmune Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ADAP, but not buy additional shares or sell existing shares.
View analyst ratings for Adaptimmune Therapeutics
or view top-rated stocks.

How has Adaptimmune Therapeutics' stock price been impacted by Coronavirus?

Adaptimmune Therapeutics' stock was trading at $2.94 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ADAP stock has increased by 22.1% and is now trading at $3.59.
View which stocks have been most impacted by COVID-19
.

When is Adaptimmune Therapeutics' next earnings date?

Adaptimmune Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Adaptimmune Therapeutics
.

How were Adaptimmune Therapeutics' earnings last quarter?

Adaptimmune Therapeutics plc (NASDAQ:ADAP) issued its quarterly earnings results on Thursday, November, 4th. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.26) by $0.04. Adaptimmune Therapeutics had a negative net margin of 2,499.92% and a negative trailing twelve-month return on equity of 53.31%. During the same quarter last year, the firm earned ($0.23) earnings per share.
View Adaptimmune Therapeutics' earnings history
.

What price target have analysts set for ADAP?

5 Wall Street analysts have issued 12-month price objectives for Adaptimmune Therapeutics' stock. Their forecasts range from $4.00 to $15.00. On average, they expect Adaptimmune Therapeutics' share price to reach $8.40 in the next year. This suggests a possible upside of 134.0% from the stock's current price.
View analysts' price targets for Adaptimmune Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Adaptimmune Therapeutics' key executives?

Adaptimmune Therapeutics' management team includes the following people:
  • Adrian Rawcliffe, Chief Executive Officer & Director (LinkedIn Profile)
  • William C. Bertrand, Chief Operating Officer
  • Gavin Wood, Chief Financial Officer
  • Elliot Norry, Chief Medical Officer
  • Helena Katrina Tayton-Martin, Chief Business Officer

What is Adrian Rawcliffe's approval rating as Adaptimmune Therapeutics' CEO?

6 employees have rated Adaptimmune Therapeutics CEO Adrian Rawcliffe on Glassdoor.com. Adrian Rawcliffe has an approval rating of 100% among Adaptimmune Therapeutics' employees. This puts Adrian Rawcliffe in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Adaptimmune Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adaptimmune Therapeutics investors own include Zynerba Pharmaceuticals (ZYNE), CA (CA), Endologix (ELGX), Brainstorm Cell Therapeutics (BCLI), Second Sight Medical Products (EYES), Shopify (SHOP), Micron Technology (MU), BlackRock (BLK), Cara Therapeutics (CARA) and Chipotle Mexican Grill (CMG).

When did Adaptimmune Therapeutics IPO?

(ADAP) raised $150 million in an initial public offering (IPO) on Wednesday, May 6th 2015. The company issued 9,400,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch, Cowen and Company and Leerink Partners served as the underwriters for the IPO and Guggenheim Securities was co-manager.

What is Adaptimmune Therapeutics' stock symbol?

Adaptimmune Therapeutics trades on the NASDAQ under the ticker symbol "ADAP."

Who are Adaptimmune Therapeutics' major shareholders?

Adaptimmune Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (8.22%), Rock Springs Capital Management LP (1.40%), Millennium Management LLC (1.02%), Marshall Wace LLP (1.00%), BlackRock Inc. (0.81%) and Rafferty Asset Management LLC (0.47%). Company insiders that own Adaptimmune Therapeutics stock include Adrian Rawcliffe, Elliot Norry, Gavin Wood, James Noble, John Lunger, Lawrence M Alleva, Peter W Sonsini and William C Bertrand, Jr.
View institutional ownership trends for Adaptimmune Therapeutics
.

Which major investors are selling Adaptimmune Therapeutics stock?

ADAP stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Morgan Stanley, Healthcare of Ontario Pension Plan Trust Fund, SG Americas Securities LLC, Rafferty Asset Management LLC, Goldman Sachs Group Inc., GSA Capital Partners LLP, and Citigroup Inc.. Company insiders that have sold Adaptimmune Therapeutics company stock in the last year include Adrian Rawcliffe, Elliot Norry, John Lunger, and William C Bertrand, Jr.
View insider buying and selling activity for Adaptimmune Therapeutics
or view top insider-selling stocks.

Which major investors are buying Adaptimmune Therapeutics stock?

ADAP stock was bought by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Baillie Gifford & Co., Millennium Management LLC, Rock Springs Capital Management LP, Eversept Partners LP, BlackRock Inc., Balyasny Asset Management LLC, and Balyasny Asset Management LLC. Company insiders that have bought Adaptimmune Therapeutics stock in the last two years include Gavin Wood, Lawrence M Alleva, Peter W Sonsini, and William C Bertrand, Jr.
View insider buying and selling activity for Adaptimmune Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Adaptimmune Therapeutics?

Shares of ADAP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Adaptimmune Therapeutics' stock price today?

One share of ADAP stock can currently be purchased for approximately $3.59.

How much money does Adaptimmune Therapeutics make?

Adaptimmune Therapeutics has a market capitalization of $560.77 million and generates $3.96 million in revenue each year. The biotechnology company earns $-130.09 million in net income (profit) each year or ($0.99) on an earnings per share basis.

How many employees does Adaptimmune Therapeutics have?

Adaptimmune Therapeutics employs 2,020 workers across the globe.

What is Adaptimmune Therapeutics' official website?

The official website for Adaptimmune Therapeutics is www.adaptimmune.com.

Where are Adaptimmune Therapeutics' headquarters?

Adaptimmune Therapeutics is headquartered at 60 JUBILEE AVENUE MILTON PARK OXFORDSHIRE, ABINGDON X0, OX14 4RX.

How can I contact Adaptimmune Therapeutics?

Adaptimmune Therapeutics' mailing address is 60 JUBILEE AVENUE MILTON PARK OXFORDSHIRE, ABINGDON X0, OX14 4RX. The biotechnology company can be reached via phone at 441235430000, via email at [email protected], or via fax at 44-12-3543-0001.


This page was last updated on 12/6/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.